![Joseph Pearlberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joseph Pearlberg
Directeur/Membre du Conseil chez
NUVALENT, INC.
Fortune : 568 067 $ au 31/05/2026
Profil
Joseph Pearlberg is an Independent Director at Nuvalent, Inc. since 2021.
Dr. Pearlberg is a Director at Neomorph, Inc. Dr. Pearlberg is an Associate at The Broad Institute, Inc. Dr. Pearlberg is Vice President at Deerfield Management Co. LP (Private Equity) since 2017.
Dr. Pearlberg was Medical Director at Sanofi.
Dr. Pearlberg was Vice President-Clinical Development at Infinity Pharmaceuticals, Inc. from 2016 to 2017.
Dr. Pearlberg earned a doctorate from Harvard University in 1994.
Dr. Pearlberg earned an undergraduate degree from the University of Pennsylvania in 1985.
Dr. Pearlberg earned a doctorate from The University of California, San Francisco in 1999.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUVALENT, INC. CLASS A 0,01 % | 18/06/2025 | 5 146 ( 0,01 % ) | 568 067 $ | 31/05/2026 |
Postes actifs de Joseph Pearlberg
| Sociétés | Poste | Début |
|---|---|---|
| NUVALENT, INC. | Directeur/Membre du Conseil | 01/01/2021 |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Corporate Officer/Principal | - |
Neomorph, Inc.
 Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Directeur/Membre du Conseil | - |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Private Equity Investor | 01/07/2017 |
Anciens postes connus de Joseph Pearlberg
| Sociétés | Poste | Fin |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2017 |
| SANOFI | Directeur Technique/Scientifique/R&D | - |
Formation de Joseph Pearlberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Finance |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Health Technology |
